RBr042 inhaled for chronic respiratory disease
Our most advanced drug, RBr042, is an inhaled RNA therapeutic, a 'splice-switching oligonucleotide' or SSO, which increases esRAGE and decreases RAGE activation in the lung. esRAGE is a naturally occurring, anti-inflammatory spliceoform of RAGE.
RBr042 is being developed for chronic inflammatory lung diseases, including COPD, in which disease severity correlates with reductions in esRAGE.
RBr042 is designed to switch the equilibrium back towards healthy levels of esRAGE, inhibit pro-inflammatory RAGE signalling, and protect the lung against further damage.